Â鶹ÊÓƵ

Phil Oakley analyses the quality of growth at a corporate payments company and private medical services provider

These energy mainstays are undergoing massive change.

The investment thesis has changed significantly for both a dividend stalwart and a leading housebuilder, says Robin Hardy

A past-maligned stock on a good run, or a former stalwart in a rut - which is the best buy?

How sustainable are these seemingly robust dividend payments?

These US companies will be ripe to re-rate once Fed policy eases.

Well-executed business models in structural growth markets.

Some stocks may be technically undervalued but it is right that more risk is priced in.

Phil Oakley examines a re-rate story and an AI support play.

A cheaper connectivity business plus an attractively priced trading firm.